GlassScriptPhysician profile
Michael Manansala
NPI 1841665411
$8,371.76
in general payments reported to CMS, 2019-2025
12 companies · $6,339 in 2025
The $6,339 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $597 · 2024: $1,435 · 2025: $6,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150 · Consulting Fee: $2,280 · Travel and Lodging: $882 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.96 |
| Consulting Fee | $2,280.00 |
| Travel and Lodging | $881.81 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,720.87 | 2024-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,186.51 | 2025 | |
| Abbvie INC. | $696.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $577.52 | 2023-2025 | Benlysta, Nucala |
| Ucb, INC. | $536.85 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $477.04 | 2024-2025 | Tavneos, Otezla, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.16 | 2023-2025 | Ofev |
| Janssen Scientific Affairs, LLC | $267.26 | 2023-2025 | Tremfya |
| Pfizer INC. | $152.70 | 2024-2025 | |
| Octapharma USA, INC. | $124.87 | 2024 | Octagam Immune Globulin (Human) |
| Astrazeneca Pharmaceuticals LP | $103.51 | 2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $60.47 | 2024-2025 | Sotyktu, Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Manansala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.